These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7621560)

  • 1. An audit of oestradiol levels and implant frequency in women undergoing subcutaneous implant therapy.
    Buckler HM; Kalsi PK; Cantrill JA; Anderson DC
    Clin Endocrinol (Oxf); 1995 May; 42(5):445-50. PubMed ID: 7621560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-related effects of a progestogen on the isoforms of serum gonadotrophins in 17 beta-oestradiol treated post-menopausal women.
    Wide L; Naessén T; Eriksson K; Rune C
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):651-8. PubMed ID: 8759177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of chronic daily oral administration of 17 beta-oestradiol and norethisterone on the isoforms of serum gonadotrophins in post-menopausal women.
    Wide L; Naessén T; Phillips DJ
    Clin Endocrinol (Oxf); 1995 Jan; 42(1):59-64. PubMed ID: 7889633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmenopausal oestrogen replacement therapy with subcutaneous oestradiol implants.
    Suhonen S; Sipinen S; Lähteenmäki P; Laine H; Rainio J; Arko H
    Maturitas; 1993 Mar; 16(2):123-31. PubMed ID: 8483424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintained bone density at advanced ages after long term treatment with low dose oestradiol implants.
    Naessén T; Persson I; Thor L; Mallmin H; Ljunghall S; Bergström R
    Br J Obstet Gynaecol; 1993 May; 100(5):454-9. PubMed ID: 8518246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?
    Owen EJ; Siddle NC; McGarrigle HT; Pugh MA
    Br J Obstet Gynaecol; 1992 Aug; 99(8):671-5. PubMed ID: 1327094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological oestradiol administration does not change the biological to immunological ratio of LH in serum from post-menopausal women.
    Buckler HM; Rothwell C; Hollis S; Robertson WR
    Clin Endocrinol (Oxf); 1993 May; 38(5):481-5. PubMed ID: 8330444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone implants and tachyphylaxis.
    Garnett T; Studd JW; Henderson A; Watson N; Savvas M; Leather A
    Br J Obstet Gynaecol; 1990 Oct; 97(10):917-21. PubMed ID: 2223683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An audit of oestrogen implant hormone replacement therapy.
    Templeman C; Quinn D; Hansen R; Moreton T; Baber R
    Aust N Z J Obstet Gynaecol; 1998 Nov; 38(4):455-60. PubMed ID: 9890234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of 25 mg and 50 mg oestradiol implants in the control of climacteric symptoms following hysterectomy and bilateral salpingo-oophorectomy.
    Panay N; Versi E; Savvas M
    BJOG; 2000 Aug; 107(8):1012-6. PubMed ID: 10955434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women.
    Wheatley S; Bell RJ; Stuckey BG; Robinson PJ; Davis SR
    Maturitas; 2016 Dec; 94():84-86. PubMed ID: 27823750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17 beta-oestradiol counteracts the formation of the more acidic isoforms of follicle-stimulating hormone and luteinizing hormone after menopause.
    Wide L; Naessén T
    Clin Endocrinol (Oxf); 1994 Jun; 40(6):783-9. PubMed ID: 8033370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adequacy of hormone replacement therapy for osteoporosis prevention assessed by serum oestradiol measurement, and the degree of association with menopausal symptoms.
    Rodgers M; Miller JE
    Br J Gen Pract; 1997 Mar; 47(416):161-5. PubMed ID: 9167320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral oestrogens.
    Savvas M; Studd JW; Norman S; Leather AT; Garnett TJ; Fogelman I
    Br J Obstet Gynaecol; 1992 Sep; 99(9):757-60. PubMed ID: 1420016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women.
    Savvas M; Studd JW; Fogelman I; Dooley M; Montgomery J; Murby B
    BMJ; 1988 Jul; 297(6644):331-3. PubMed ID: 3137998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are high levels of oestradiol after implants associated with features of dependence?
    O'Leary A; Bowen-Simpkins P; Tejura H; Rajesh U
    Br J Obstet Gynaecol; 1999 Sep; 106(9):960-3. PubMed ID: 10492109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dose-response of percutaneous oestradiol implants on the skeletons of postmenopausal women.
    Studd JW; Holland EF; Leather AT; Smith RN
    Br J Obstet Gynaecol; 1994 Sep; 101(9):787-91. PubMed ID: 7947528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous hormone implants for the control of climacteric symptoms. A prospective study.
    Brincat M; Magos A; Studd JW; Cardozo LD; O'Dowd T; Wardle PJ; Cooper D
    Lancet; 1984 Jan; 1(8367):16-8. PubMed ID: 6140343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous implantation of pure crystalline estradiol pellets for conception control.
    Oettinger M; Barak S; Oettinger-Barak O; Ophira E
    Gynecol Obstet Invest; 2005; 59(3):119-25. PubMed ID: 15591820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal profiles in postmenopausal women after therapy with subcutaneous implants.
    Thom MH; Collins WP; Studd JW
    Br J Obstet Gynaecol; 1981 Apr; 88(4):426-33. PubMed ID: 6784745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.